Drug General Information |
Drug ID |
D0E8VF
|
Former ID |
DNC000787
|
Drug Name |
IMC-1C11
|
Drug Type |
Antibody
|
Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Discontinued in Phase 1 |
[1]
|
CAS Number |
CAS 543726-73-4
|
PubChem Substance ID |
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
|
[2]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Proteoglycans in cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
VEGF and VEGFR signaling network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY network
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferation
|
WikiPathways
|
Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
Signaling by VEGF
|
Angiogenesis
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013121) |
---|
REF 2 | Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther. 2001 Aug;3(4):418-24. |